Cargando…
Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study
Twenty-one adult patients were randomised to receive ghrelin on days 1 and 8 and placebo on days 4 and 11 or vice versa, given intravenously over a 60-min period before lunch: 10 received 2 μg kg(−1) (lower-dose) ghrelin; 11 received 8 μg kg(−1) (upper-dose) ghrelin. Active and total ghrelin, growth...
Autores principales: | Strasser, F, Lutz, T A, Maeder, M T, Thuerlimann, B, Bueche, D, Tschöp, M, Kaufmann, K, Holst, B, Brändle, M, von Moos, R, Demmer, R, Cerny, T |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361459/ https://www.ncbi.nlm.nih.gov/pubmed/18182992 http://dx.doi.org/10.1038/sj.bjc.6604148 |
Ejemplares similares
-
Natural ghrelin in advanced cancer patients with cachexia, a case series
por: Blum, David, et al.
Publicado: (2021) -
Plasma Ghrelin Levels Are Associated with Anorexia but Not Cachexia in Patients with NSCLC
por: Blauwhoff-Buskermolen, Susanne, et al.
Publicado: (2017) -
Rikkunshito, a ghrelin potentiator, ameliorates anorexia–cachexia syndrome
por: Fujitsuka, Naoki, et al.
Publicado: (2014) -
Potentiation of ghrelin signaling attenuates cancer anorexia–cachexia and prolongs survival
por: Fujitsuka, N, et al.
Publicado: (2011) -
Ghrelin for cachexia
por: Akamizu, Takashi, et al.
Publicado: (2010)